larotrectinib   Click here for help

GtoPdb Ligand ID: 8909

Synonyms: (S)-N-(5-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide [3] | example 14 [US8865698 B2] [3] | LOXO-101 | Vitrakvi®
Approved drug
larotrectinib is an approved drug (FDA (2018), EMA (2019))
Compound class: Synthetic organic
Comment: Larotrectinib (LOXO-101) is an orally available, potent and selective inhibitor of the receptor tyrosine kinases of the TRK family [2-3]. In these referenced patents, data is provided for inhibition of neurotrophic tyrosine kinase, receptor, type 1 (NTRK1, a.k.a. TrkA) .
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 7
Hydrogen bond donors 2
Rotatable bonds 5
Topological polar surface area 86
Molecular weight 428.18
XLogP 3.07
No. Lipinski's rules broken 0
Click here for help
Canonical SMILES OC1CCN(C1)C(=O)Nc1cnn2c1nc(cc2)N1CCCC1c1cc(F)ccc1F
Isomeric SMILES O[C@H]1CCN(C1)C(=O)Nc1cnn2c1nc(cc2)N1CCC[C@@H]1c1cc(F)ccc1F
InChI InChI=1S/C21H22F2N6O2/c22-13-3-4-16(23)15(10-13)18-2-1-7-28(18)19-6-9-29-20(26-19)17(11-24-29)25-21(31)27-8-5-14(30)12-27/h3-4,6,9-11,14,18,30H,1-2,5,7-8,12H2,(H,25,31)/t14-,18+/m0/s1
1. Drilon A, Laetsch TW, Kummar S, DuBois SG, Lassen UN, Demetri GD, Nathenson M, Doebele RC, Farago AF, Pappo AS et al.. (2018)
Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children.
N Engl J Med, 378 (8): 731-739. [PMID:29466156]
2. Haas J, Andrews SW, Jiang Y, Zhang G. (2010)
Substituted pyrazolo[1,5-a]pyrimidine compounds as TRK kinase inhibitors.
Patent number: WO2010048314 A1. Assignee: Array Biopharma Inc.. Priority date: 22/10/2008. Publication date: 29/04/2010.
3. Haas J, Andrews SW, Jiang Y, Zhang G. (2014)
Method of treatment using substituted pyrazolo[1,5-a]pyrimidine compounds.
Patent number: US8865698 B2. Assignee: Array Biopharma Inc.. Priority date: 22/10/2008. Publication date: 21/10/2014.
4. Scott LJ. (2019)
Larotrectinib: First Global Approval.
Drugs, 79 (2): 201-206. [PMID:30635837]